Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2305]

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM...

Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients ( Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain )

Evaluation of MRD negativity in patients with relapsed or refractory multiple...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

$Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )$

Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in...

Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA

Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in newly diagnosed or R/R AML ( Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA )

Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )

Ponatinib, venetoclax and dexamethasone for patients with relapsed or...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

$Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )$

Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic...

Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA

Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia ( Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA )

PARP inhibitors in prostate cancer: A promise delivered

Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA

PARP inhibitors in prostate cancer: A promise delivered ( Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA )

Targeting a KRAS neoantigen peptide vaccine to DNGR-1 dendritic cells

Dr Rachel Ambler - The Francis Crick Institute, London, United Kingdom

Targeting a KRAS neoantigen peptide vaccine to DNGR-1 dendritic cells ( Dr Rachel Ambler - The Francis Crick Institute, London, United Kingdom )

OncoAlert and ecancer weekly roundup for November 15 - 21, 2020

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for November 15 - 21, 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Clinical genomic testing in prostate cancer

Laurie M Connors - Vanderbilt University School of Nursing, Nashville, USA

Clinical genomic testing in prostate cancer ( Laurie M Connors - Vanderbilt University School of Nursing, Nashville, USA )

PARP inhibitors for prostate cancer - Nurse's view

Laurie M. Connors - Vanderbilt University School of Nursing, Nashville, USA

PARP inhibitors for prostate cancer - Nurse's view ( Laurie M. Connors - Vanderbilt University School of Nursing, Nashville, USA )

Predictors of efficacy in patients with HR positive/HER2 negative ABC: Subgroup...

Prof Hope Rugo - University of California, San Francisco, USA

Predictors of efficacy in patients with HR positive/HER2 negative ABC: Subgroup analyses of PALOMA-3 ( Prof Hope Rugo - University of California, San Francisco, USA )

More from ecancer